Epigenetic editing and tumor‑dependent immunosuppressive signaling in head and neck malignancies (Review)
- Authors:
- Spyridon Gougousis
- Savvas Petanidis
- Alexandros Poutoglidis
- Nikolaos Tsetsos
- Paraskevas Vrochidis
- Ioannis Skoumpas
- Nektarios Argyriou
- Theodora Katopodi
- Kalliopi Domvri
-
Affiliations: Ear Nose Throat Department, General Hospital of Thessaloniki ‘G. Papanikolaou’, Thessaloniki GR‑57010, Greece, Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, Moscow 119992, Russian Federation, Ear Nose Throat Department, General Hospital of Goumenissa, Kilkis GR‑61100, Greece, Ear Nose Throat Department, General Hospital of Katerini, Katerini GR‑60100, Greece, Ear Nose Throat Department, General Hospital of Thessaloniki ‘G. Gennimatas’, Thessaloniki GR‑54635, Greece, Department of Medicine, Laboratory of Medical Biology and Genetics, Aristotle University of Thessaloniki, Thessaloniki GR‑54124, Greece, Pulmonary Department, General Hospital of Thessaloniki ‘G. Papanikolaou’, Aristotle University of Thessaloniki, Thessaloniki GR‑57010, Greece - Published online on: May 4, 2022 https://doi.org/10.3892/ol.2022.13317
- Article Number: 196
-
Copyright: © Gougousis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Auperin A: Epidemiology of head and neck cancers: An update. Curr Opin Oncol. 32:178–186. 2020. View Article : Google Scholar | |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Dos Santos ES, Wagner VP, Cabral Ramos J, Lambert DW, Castilho RM and Paes Leme AF: Epigenetic modulation of the tumor microenvironment in head and neck cancer: Challenges and opportunities. Crit Rev Oncol Hematol. 164:1033972021. View Article : Google Scholar | |
|
Prime SS, Thakker NS, Pring M, Guest PG and Paterson IC: A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol. 37:1–16. 2001. View Article : Google Scholar | |
|
Bennardo L, Bennardo F, Giudice A, Passante M, Dastoli S, Morrone P, Provenzano E, Patruno C and Nisticò SP: Local chemotherapy as an adjuvant treatment in unresectable squamous cell carcinoma: What do we know so far? Curr Oncol. 28:2317–2325. 2021. View Article : Google Scholar | |
|
Pentangelo G, Nisticò SP, Provenzano E, Cisale GY and Bennardo L: Topical 5% imiquimod sequential to surgery for HPV-related squamous cell carcinoma of the lip. Medicina (Kaunas). 57:5632021. View Article : Google Scholar : PubMed/NCBI | |
|
Venugopal R, Bavle RM, Konda P, Muniswamappa S and Makarla S: Familial cancers of head and neck region. J Clin Diagn Res. 11:ZE01–ZE06. 2017.PubMed/NCBI | |
|
Plavc G, Jesenko T, Oražem M and Strojan P: Challenges in combining immunotherapy with radiotherapy in recurrent/metastatic head and neck cancer. Cancers (Basel). 12:31972020. View Article : Google Scholar | |
|
Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, Moros EG and Harrison LB: The future of personalised radiotherapy for head and neck cancer. Lancet Oncol. 18:e266–e273. 2017. View Article : Google Scholar | |
|
Bakhtiar SM, Ali A and Barh D: Epigenetics in head and neck cancer. Methods Mol Biol. 1238:751–769. 2015. View Article : Google Scholar | |
|
Gazdzicka J, Golabek K, Strzelczyk JK and Ostrowska Z: Epigenetic modifications in head and neck cancer. Biochem Genet. 58:213–244. 2020. View Article : Google Scholar | |
|
Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65:6321–6329. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chiappinelli KB, Zahnow CA, Ahuja N and Baylin SB: Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 76:1683–1689. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dunn J and Rao S: Epigenetics and immunotherapy: The current state of play. Mol Immunol. 87:227–239. 2017. View Article : Google Scholar | |
|
Leemans CR, Snijders PJF and Brakenhoff RH: The molecular landscape of head and neck cancer. Nat Rev Cancer. 18:269–282. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ferris RL: Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 33:3293–3304. 2015. View Article : Google Scholar | |
|
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al: Avelumab plus Axitinib versus sunitinib for advanced Renal-Cell carcinoma. N Engl J Med. 380:1103–1115. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chu L, Chen Y, Liu Q, Liang F, Wang S, Liu Q, Yu H, Wu X, Zhang J, Deng J, et al: A phase II study of apatinib in patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESO-Shanghai 11). Oncologist. 26:e925–e935. 2021. View Article : Google Scholar | |
|
Mollica Poeta V, Massara M, Capucetti A and Bonecchi R: Chemokines and Chemokine receptors: New targets for cancer immunotherapy. Front Immunol. 10:3792019. View Article : Google Scholar | |
|
Pooler DB, Ness DB, Sarantopoulos J, Squittieri N, Ravichandran S, Britten CD, Amaravadi RK, Vaishampayan U, LoRusso P, Shapiro GI, et al: The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. Br J Clin Pharmacol. 87:1291–1302. 2021. View Article : Google Scholar | |
|
Karam SD and Raben D: Radioimmunotherapy for the treatment of head and neck cancer. Lancet Oncol. 20:e404–e416. 2019. View Article : Google Scholar | |
|
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019. View Article : Google Scholar | |
|
Billan S, Kaidar-Person O and Gil Z: Treatment after progression in the era of immunotherapy. Lancet Oncol. 21:e463–e476. 2020. View Article : Google Scholar | |
|
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021. View Article : Google Scholar | |
|
Tarhini AA: Tremelimumab: A review of development to date in solid tumors. Immunotherapy. 5:215–229. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Han L, Sheng Y and Wu S: Cetuximab monotherapy for relapsing high-grade mucoepidermoid carcinoma: A case report and review of the literature. Oral Oncol. 107:1048242020. View Article : Google Scholar | |
|
Chester C, Sanmamed MF, Wang J and Melero I: Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies. Blood. 131:49–57. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R and Chinot OL: Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 86:1020172020. View Article : Google Scholar : PubMed/NCBI | |
|
Scagliotti GV, Novello S and von Pawel J: The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 39:793–801. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shih YH, Chen PC and Chu CY: Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib. J Clin Oncol. 31:e335–e337. 2013. View Article : Google Scholar | |
|
Greiner JW, Morillon YM II and Schlom J: NHS-IL12, a tumor-targeting immunocytokine. Immunotargets Ther. 10:155–169. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PA: Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet. 13:484–492. 2012. View Article : Google Scholar | |
|
Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, et al: Analysis of DNA methylation in cancer: Location revisited. Nat Rev Clin Oncol. 15:459–466. 2018. View Article : Google Scholar | |
|
Klutstein M, Nejman D, Greenfield R and Cedar H: DNA methylation in cancer and aging. Cancer Res. 76:3446–3450. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA and Laird PW: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61:3410–3418. 2001.PubMed/NCBI | |
|
Chen Y, Jiang X, Li X, Yan D, Liu J, Yang J and Yan S: The methylation modification of m6A regulators contributes to the prognosis of head and neck squamous cell carcinoma. Ann Transl Med. 9:13462021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C, Ye M, Ni S, Li Q, Ye D, Li J, Shen Z and Deng H: DNA methylation biomarkers for head and neck squamous cell carcinoma. Epigenetics. 13:398–409. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hier J, Vachon O, Bernstein A, Ibrahim I, Mlynarek A, Hier M, Alaoui-Jamali MA, Maschietto M and da Silva SD: Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy. Sci Rep. 11:100122021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao JJ, Li HY, Wang D, Yao H and Sun DW: Abnormal MGMT promoter methylation may contribute to the risk of esophageal cancer: A meta-analysis of cohort studies. Tumour Biol. 35:10085–10093. 2014. View Article : Google Scholar | |
|
Ji X, Guan C, Jiang X and Li H: Diagnostic accuracy of DNA methylation for head and neck cancer varies by sample type and number of markers tested. Oncotarget. 7:80019–80032. 2016. View Article : Google Scholar | |
|
Koutsimpelas D, Pongsapich W, Heinrich U, Mann S, Mann WJ and Brieger J: Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: Pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Oncol Rep. 27:1135–1141. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schmitt K, Molfenter B, Laureano NK, Tawk B, Bieg M, Hostench XP, Weichenhan D, Ullrich ND, Shang V, Richter D, et al: Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer. Int J Cancer. 145:3299–3310. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ban Y, Tan P, Cai J, Li J, Hu M, Zhou Y, Mei Y, Tan Y, Li X, Zeng Z, et al: LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Mol Oncol. 14:1282–1296. 2020. View Article : Google Scholar | |
|
Bai G, Song J, Yuan Y, Chen Z, Tian Y, Yin X, Niu Y and Liu J: Systematic analysis of differentially methylated expressed genes and site-specific methylation as potential prognostic markers in head and neck cancer. J Cell Physiol. 234:22687–22702. 2019. View Article : Google Scholar | |
|
Misawa K, Mochizuki D, Endo S, Mima M, Misawa Y, Imai A, Shinmura K, Kanazawa T, Carey TE and Mineta H: Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis. Mol Carcinog. 56:1107–1116. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Misawa K, Imai A, Matsui H, Kanai A, Misawa Y, Mochizuki D, Mima M, Yamada S, Kurokawa T, Nakagawa T and Mineta H: Identification of novel methylation markers in HPV-associated oropharyngeal cancer: Genome-wide discovery, tissue verification and validation testing in ctDNA. Oncogene. 39:4741–4755. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Castilho RM, Squarize CH and Almeida LO: Epigenetic modifications and head and neck cancer: Implications for tumor progression and resistance to therapy. Int J Mol Sci. 18:15062017. View Article : Google Scholar | |
|
Chang S, Yim S and Park H: The cancer driver genes IDH1/2, JARID1C/KDM5C, and UTX/KDM6A: Crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Exp Mol Med. 51:1–17. 2017. View Article : Google Scholar | |
|
Ma H, Chang H, Yang W, Lu Y, Hu J and Jin SA: Novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma. Mol Cancer. 19:42020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou L, Mudianto T, Ma X, Riley R and Uppaluri R: Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer. Clin Cancer Res. 26:290–300. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Chen W, Lian J, Zhang H, Yu B, Zhang M, Wei F, Wu J, Jiang J, Jia Y, et al: The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1α. Cell Death Differ. 27:695–710. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang E, Han L, Yin D, He X, Hong L, Si X, Qiu M, Xu T, De W, Xu L, et al: H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res. 45:3086–3101. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kadoch C: Diverse compositions and functions of chromatin remodeling machines in cancer. Sci Transl Med. 11:eaay10182019. View Article : Google Scholar : PubMed/NCBI | |
|
Yi M, Tan Y, Wang L, Cai J, Li X, Zeng Z, Xiong W, Li G, Li X, Tan P and Xiang B: TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development. Cell Mol Life Sci. 77:4325–4346. 2020. View Article : Google Scholar | |
|
Portney BA, Arad M, Gupta A, Brown RA, Khatri R, Lin PN, Hebert AM, Angster KH, Silipino LE, Meltzer WA, et al: ZSCAN4 facilitates chromatin remodeling and promotes the cancer stem cell phenotype. Oncogene. 39:4970–4982. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I and Liu FF: Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget. 3:1641–1652. 2012. View Article : Google Scholar | |
|
He X, Yan B, Liu S, Jia J, Lai W, Xin X, Tang CE, Luo D, Tan T, Jiang Y, et al: Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. Cancer Res. 76:5743–5755. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Saladi SV, Ross K, Karaayvaz M, Tata PR, Mou H, Rajagopal J, Ramaswamy S and Ellisen LW: ACTL6A Is Co-Amplified with p63 in squamous cell carcinoma to drive YAP activation, regenerative proliferation, and poor prognosis. Cancer Cell. 31:35–49. 2017. View Article : Google Scholar | |
|
Quinn JJ and Chang HY: Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 17:47–62. 2016. View Article : Google Scholar | |
|
Kopp F and Mendell JT: Functional classification and experimental dissection of long noncoding RNAs. Cell. 172:393–407. 2018. View Article : Google Scholar | |
|
Wang R, Ma Z, Feng L, Yang Y, Tan C, Shi Q, Lian M, He S, Ma H and Fang J: LncRNA MIR31HG targets HIF1A and P21 to facilitate head and neck cancer cell proliferation and tumorigenesis by promoting cell-cycle progression. Mol Cancer. 17:1622017. View Article : Google Scholar | |
|
Jiangm Y, Cao W, Wu K, Qin X, Wang X, Li Y, Yu B, Zhang Z, Wang X, Yan M, et al: LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus. J Exp Clin Cancer Res. 38:3652019. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan J, Song Y, Pan W, Li Y, Xu Y, Xie M, Shen Y, Zhang N, Liu J, Hua H, et al: LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5. Oncogene. 39:6664–6676. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong HG, Li H, Xiao Y, Yang QC, Yang LL, Chen L, Bu LL, Zhang WF, Zhang JL and Sun ZJ: Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 38:2782019. View Article : Google Scholar : PubMed/NCBI | |
|
Kristensen LS, Hansen TB, Venø MT and Kjems J: Circular RNAs in cancer: Opportunities and challenges in the field. Oncogene. 37:555–565. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Goodall GJ and Wickramasinghe VO: RNA in cancer. Nat Rev Cancer. 21:22–36. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bi W, Huang J, Nie C, Liu B, He G, Han J, Pang R, Ding Z, Xu J and Zhang J: CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of β-catenin pathway. J Exp Clin Cancer Res. 37:2752018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Zhang S, Wu J, Cui J, Zhong L, Zeng L and Ge S: CircRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family. Oncogene. 36:4551–4561. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Verduci L, Ferraiuolo M, Sacconi A, Ganci F, Vitale J, Colombo T, Paci P, Strano S, Macino G, Rajewsky N and Blandino G: The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biol. 18:2372017. View Article : Google Scholar | |
|
Hu X, Wu D, He X, Zhao H, He Z, Lin J, Wang K, Wang W, Pan Z, Lin H and Wang M: circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling. Mol Cancer. 18:1602019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Xue N, Guo Y, Niu K, Gao L, Zhang S, Gu H, Wang X, Zhao D and Fan R: CircRNA_100367 regulated the radiation sensitivity of esophageal squamous cell carcinomas through miR-217/Wnt3 pathway. Aging (Albany NY). 11:12412–12427. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, Xu Q, Shi J, Lu E, Chen W and Zhang J: Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 20:122019. View Article : Google Scholar | |
|
Yu B, Wu K, Wang X, Zhang J, Wang L, Jiang Y, Zhu X, Chen W and Yan M: Periostin secreted by cancer-associated fibroblasts promotes cancer stemness in head and neck cancer by activating protein tyrosine kinase 7. Cell Death Dis. 9:10822018. View Article : Google Scholar : PubMed/NCBI | |
|
New J, Arnold L, Ananth M, Alvi S, Thornton M, Werner L, Tawfik O, Dai H, Shnayder Y, Kakarala K, et al: Secretory autophagy in cancer-associated fibroblasts promotes head and neck cancer progression and offers a novel therapeutic target. Cancer Res. 77:6679–6691. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Qin X, Yan M, Wang X, Xu Q, Wang X, Zhu X, Shi J, Li Z, Zhang J and Chen W: Cancer-associated fibroblast-derived IL-6 promotes head and neck cancer progression via the osteopontin-NF-kappa B signaling pathway. Theranostics. 8:921–940. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi H, Sakakura K, Kudo T, Toyoda M, Kaira K, Oyama T and Chikamatsu K: Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages. Oncotarget. 8:8633–8647. 2017. View Article : Google Scholar | |
|
Davis RJ, Van Waes C and Allen CT: Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 58:59–70. 2016. View Article : Google Scholar | |
|
Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, et al: Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models. Clin Cancer Res. 26:1420–1431. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, et al: STAT3 modulation of regulatory T cells in response to radiation therapy in head and neck cancer. J Natl Cancer Inst. 111:1339–1349. 2019. View Article : Google Scholar | |
|
Kwak T, Wang F, Deng H, Condamine T, Kumar V, Perego M, Kossenkov A, Montaner LJ, Xu X, Xu W, et al: Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer. Cell Rep. 33:1085712020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang CX, Ye SB, Ni JJ, Cai TT, Liu YN, Huang DJ, Mai HQ, Chen QY, He J, Zhang XS, et al: STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 26:2314–2328. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cai TT, Ye SB, Liu YN, He J, Chen QY, Mai HQ, Zhang CX, Cui J, Zhang XS, Busson P, et al: LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. PLoS Pathog. 13:e10065032017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JF, Ma SR, Mao L, Bu LL, Yu GT, Li YC, Huang CF, Deng WW, Kulkarni AB, Zhang WF and Sun ZJ: T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer. Mol Oncol. 11:235–247. 2017. View Article : Google Scholar | |
|
Larionova I, Cherdyntseva N, Liu T, Patysheva M, Rakina M and Kzhyshkowska J: Interaction of tumor-associated macrophages and cancer chemotherapy. Oncoimmunology. 8:15960042019. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh CH, Tai SK and Yang MH: Snail-overexpressing cancer cells promote M2-Like polarization of tumor-associated macrophages by delivering MiR-21-Abundant Exosomes. Neoplasia. 20:775–788. 2018. View Article : Google Scholar | |
|
Cao MX, Zhang WL, Yu XH, Wu JS, Qiao XW, Huang MC, Wang K, Wu JB, Tang YJ, Jiang J, et al: Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression. J Exp Clin Cancer Res. 39:1022020. View Article : Google Scholar : PubMed/NCBI | |
|
Rigo A, Gottardi M, Zamò A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G and Vinante F: Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer. 9:2732010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang F, Li P, Liu S, Yang M, Zeng S, Deng J, Chen D, Yi Y and Liu H: β-Catenin-CCL2 feedback loop mediates crosstalk between cancer cells and macrophages that regulates breast cancer stem cells. Oncogene. 40:5854–5865. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao M, Zhang J and Chen W and Chen W: M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma. J Exp Clin Cancer Res. 37:1432018. View Article : Google Scholar : PubMed/NCBI |
